JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

S. Lu; J. Zhou; X. Niu; M. Chen; Y. Hua; W. Su

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

【24h】

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

机译：JCES 01.12 JCES 01.12 A II期与患有EGFR激活突变的IIIB / IV NSCLC患者的吉替尼结合的II期研究

获取原文

获取原文并翻译 | 示例

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第11期|共1页
作者
S. Lu; J. Zhou; X. Niu; M. Chen; Y. Hua; W. Su;
展开▼
作者单位

Shanghai Chest Hospital Shanghai Jiaotong University School of Medicine;

The First Affiliated Hospital College of Medicine Zhejiang University;

Shanghai Chest Hospital Shanghai Jiao Tong University;

Hutchison Medipharma;

Hutchison Medipharma;

Hutchison Medipharma;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献

1. JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations [J] . S. Lu, J. Zhou, X. Niu, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：JCES 01.12 JCES 01.12 A II期与患有EGFR激活突变的IIIB / IV NSCLC患者的吉替尼结合的II期研究
2. 9002 A phase III, first-line trial of gefitinib versus cisplatin plusdocetaxel for patients with advanced or recurrent non-small cell lungcancer (NSCLC) harboring activating mutation of the epidermal growthfactor receptor (EGFR) gene: a preliminary results of WJTOG 3405 [J] . J.Tsurutani, T.Mitsudomi, S.Mori, European Journal of Cancer Supplements . 2009,第2期

机译：9002 A吉非替尼与顺铂加多西他赛治疗患有晚期或复发性非小细胞肺癌（NSCLC）且具有表皮生长因子受体（EGFR）基因激活突变的患者的III期一线试验：WJTOG 3405的初步结果
3. MODEL PHARMACOECONOMIC STUDY ON IRESSA (R) (GEFITINIB) AS A FIRST LINE TREATMENT OF NON-SMALL CELL LUNG CANCER AT STAGE IIIB/IV IN EGFR MUTATION POSITIVE BULGARIAN PATIENTS [J] . Getov Ilko, Grigorov Evgeni, Naseva Emilia, Biotechnology & Biotechnological Equipment . 2013,第1期

机译：IRESSA（R）（GEFITINIB）的模型药物经济学研究作为EGFR突变阳性保加利亚患者IIIB / IV期非小细胞肺癌的一线治疗
4. Intratumor Heterogeneity of EGFR Activating Mutations in Advanced NSCLC Patients at Single-Cell Level [C] . Liu Yuefen International Conference on Biomedical Engineering, Machinery and Earth Science . 2018

机译：单细胞水平晚期NSCLC患者EGFR激活突变的细胞内异质性
5. Evaluation of Symptom Management in Patients with Advanced Stage (IIIB and IV) Non-Small Cell Lung Cancer [D] . Mann, LaTonya E. 2018

机译：晚期（IIIB和IV）非小细胞肺癌患者症状管理的评估
6. Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR [O] . Myung-Ju Ahn, Sang-We Kim, Byoung-Chul Cho, 2015

机译：阿法替尼作为三线治疗患有野生型EGFR的韩国IIIB / IV期非小细胞肺癌患者的II期研究
7. JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations [O] . S. Lu, J. Zhou, X. Niu, 2017

机译：JCES 01.12 JCES 01.12 A II期与患有EGFR激活突变的IIIB / IV NSCLC患者的吉替尼结合的II期研究

JCES 01.12 A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

著录项

相似文献

相关主题

期刊订阅